Timmermans M, et al. - Via this analysis of 11 relevant studies involving 2178 patients, researchers investigated how overall survival was influenced by the amount of residual disease following interval cytoreductive surgery in advanced ovarian cancer. They identified these studies from Medline, Embase and Cochrane via a systematic search. According to the summarized literature data, lengthened survival was observed in patients with optimal cytoreductive surgery vs patients with suboptimal cytoreductive surgery, after neoadjuvant chemotherapy. The most favorable survival outcomes, similar to what was seen following primary cytoreductive surgery, were exhibited by patients with no macroscopic residual disease.